title: Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
abstract: Physiologically based pharmacokinetic (PBPK) models are particularly useful for simulating exposures to environmental toxicants for which, unlike pharmaceuticals, there is often little or no human data available to estimate the internal dose of a putative toxic moiety in a target tissue or an appropriate surrogate. This article reviews the current state of knowledge and approaches for application of PBPK models in the process of deriving reference dose, reference concentration, and cancer risk estimates. Examples drawn from previous U.S. Environmental Protection Agency (EPA) risk assessments and human health risk assessments in peer-reviewed literature illustrate the ways and means of using PBPK models to quantify the pharmacokinetic component of the interspecies and intraspecies uncertainty factors as well as to conduct route to route, high dose to low dose and duration extrapolations. The choice of the appropriate dose metric is key to the use of the PBPK models for the various applications in risk assessment. Issues related to whether uncertainty factors are most appropriately applied before or after derivation of human equivalent dose (or concentration) continue to be explored. Scientific progress in the understanding of life stage and genetic differences in dosimetry and their impacts on variability in susceptibility, as well as ongoing development of analytical methods to characterize uncertainty in PBPK models, will make their use in risk assessment increasingly likely. As such, it is anticipated that when PBPK models are used to express adverse tissue responses in terms of the internal target tissue dose of the toxic moiety rather than the external concentration, the scientific basis of, and confidence in, risk assessments will be enhanced.
authors.affiliation: National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Washington, DC, USA.
authors.forename: Chad M
authors.initials: CM
authors.lastname: Thompson
authors.forename: Babasaheb
authors.initials: B
authors.lastname: Sonawane
authors.forename: Hugh A
authors.initials: HA
authors.lastname: Barton
authors.forename: Robert S
authors.initials: RS
authors.lastname: DeWoskin
authors.forename: John C
authors.initials: JC
authors.lastname: Lipscomb
authors.forename: Paul
authors.initials: P
authors.lastname: Schlosser
authors.forename: Weihsueh A
authors.initials: WA
authors.lastname: Chiu
authors.forename: Kannan
authors.initials: K
authors.lastname: Krishnan
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004781:Environmental Exposure; D004785:Environmental Pollutants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D008954:Models, Biological; D018570:Risk Assessment; D013045:Species Specificity; D014018:Tissue Distribution; D014481:United States; D014484:United States Environmental Protection Agency
chemical_list: D004785:Environmental Pollutants